immunomodulator is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Similarly, thermostable proteins are rich in salt bridges or/and extra disulfide bridges stabilizing the structure. Other factors of protein thermostability are compactness of protein structure, oligomerization, and strength interaction between subunits.
Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred tapping rate. These results are consistent with the drug's role in affecting prefrontal cortex activity and the role that the prefrontal cortex plays in time perception, but the neurochemical basis of psilocybin's effects on perception of time is not known with certainty. Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "bad trip") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. The term "bad trip" is generally used to describe a reaction characterized primarily by fear or other unpleasant emotions, not just a transitory experience of such feelings. A variety of factors may contribute to a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: set and setting). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip. Other than the duration of the experience, the effects of psilocybin are similar to comparable doses of lysergic acid diethylamide (LSD) or mescaline.
=== Gluten related disorders === Gluten is a structural protein naturally found in certain cereal grains, in the medical literature gluten is referred as the combination of prolamin and glutelin proteins naturally occurring in all grains that have been proven capable of triggering celiac disease. Specific immunogenic peptides in gliadin, a class of proteins present in wheat and several other cereals, have the ability to provoke an autoimmune enteropathy caused by an abnormal immune response in genetically susceptible individuals with coeliac disease and other gluten related disorders. Enzyme therapy for gluten related disorders proposes the use of highly targeted proline and glutamine-specific endoproteases to destroy the immunogenic gluten peptides before these interact with the intestinal lining. In vitro studies demonstrated that caricain offered a high degree of protection against the toxic action of gliadin on rat liver lysosomes and was capable of rapidly digesting the key immuno-reactive gluten epitopes associated with the pathology of celiac disease.
Sources: en.wikipedia.org
The hats of the Australian Light Horse are decorated with emu feather plumes. Trademarks of early Australian companies using the emu included Webbenderfer Bros frame mouldings (1891), Mac Robertson Chocolate and Cocoa (1893), Dyason and Son Emu Brand Cordial Sauce (1894), James Allard Pottery Wares (1906), and rope manufacturers G. Kinnear and Sons Pty. Ltd. still use it on some of their products. There are around six hundred gazetted places in Australia with "emu" in their title, including mountains, lakes, hills, plains, creeks and waterholes. During the 19th and 20th centuries, many Australian companies and household products were named after the bird. In Western Australia, Emu beer has been produced since the early 20th century and the Swan Brewery continues to produce a range of beers branded as "Emu". The quarterly peer-reviewed journal of the Royal Australasian Ornithologists Union, also known as Birds Australia, is entitled Emu: Austral Ornithology. The comedian Rod Hull featured a wayward emu puppet in his act for many years and the bird returned to the small screen in the hands of his son Toby after the puppeteer's death in 1999. In 2019, American insurance company Liberty Mutual launched an advertising campaign that features LiMu Emu, a CGI-rendered emu. The animal sanctuary, Alveus Sanctuary, has an emu named Stompy. He was their first animal ambassador, after being hand raised by the Sanctuary's founder. He is known for "giving hugs" to guests at Alveus, including Ludwig, Jaiden Animations, Jack Manifold, Hasan Piker, and Valkryae.
== Function == Studies suggest that the human sirtuins may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity. Cytosolic functions of SIRT2 include the regulation of microtubule acetylation, control of myelination in the central and peripheral nervous system and gluconeogenesis. There is growing evidence for additional functions of SIRT2 in the nucleus. During the G2/M transition, nuclear SIRT2 is responsible for global deacetylation of H4K16, facilitating H4K20 methylation and subsequent chromatin compaction. In response to DNA damage, SIRT2 was also found to deacetylate H3K56 in vivo. Finally, SIRT2 negatively regulates the acetyltransferase activity of the transcriptional co-activator p300 via deacetylation of an automodification loop within its catalytic domain.
Most notably, the oldest samples of European cheese (5500 BC) were found in the region of Kuyavia, and a pot from Bronocice is incised with what is now believed to be the earliest-known portrayal of a wheeled vehicle (3400 BC). Toolmaking became more advanced and material was primarily sourced from quarries and mines in the Świętokrzyskie (Holy Cross) Mountains. Artifacts that originated in this mountain region were excavated as far as Moravia and near the Baltic Sea. It is estimated that the UNESCO-protected neolithic flint mines at Krzemionki, one of Europe's largest, were utilised by the Funnelbeaker and Globular Amphora cultures from 3900 BC to 1600 BC. The only surviving example of ancient parietal art in Poland is at a flint shaft in Krzemionki and features a linear charcoal pictogram of a female figure or deity that has been since associated with fertility.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.